Angie Natalie Pinto

Angie Natalie Pinto

Auto-generated profile, based on publicly available information

Angie Natalie Pinto

Department of Infectious Diseases, Woodlands Hospital, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2020 in HIV Medicine
Verified
Journal Article
Closed access
PDF file
JBJd Baxter
Jd Baxter
DDD Dunn
D Dunn
ATA Tostevin
A Tostevin
RMRl Marvig
Rl Marvig
MBM Bennedbæk
M Bennedbæk
FGfor the INSIGHT START Study Group
for the INSIGHT START Study Group

13 April 2022 in Internal Medicine Journal
Verified
Journal Article
Closed access
SRSian Raubinger
Sian Raubinger
FLFrederick J. Lee
Frederick J. Lee
APAngie N. Pinto
Angie N. Pinto

29 September 2023 in HIV Medicine
Verified
Journal Article
Open access
ACAlessandro Cozzi-Lepri
Alessandro Cozzi-Lepri
DDDavid Dunn
David Dunn
ATAnna Tostevin
Anna Tostevin
RMRasmus L. Marvig
Rasmus L. Marvig
MBMarc Bennedbæk
Marc Bennedbæk
FGfor the INSIGHT START Study Group
for the INSIGHT START Study Group
Objectives: The main objective of this analysis was to evaluate the impact of pre‐existing drug resistance by next‐generation sequencing (NGS) on the risk of treatment failure (TF) of first‐line regimens in participants enrolled in the START study.Methods: Stored plasma from participants with entry HIV RNA >1000 copies/mL were analysed using NGS (llumina MiSeq). Pre‐existing drug resistance was defined using the mutations considered by the Stanford HIV Drug Resistance Database (HIVDB v8.6) to calculate the genotypic susceptibility score (GSS, estimating the number of active drugs) for the first‐line regimen at the detection threshold windows of >20%, >5%, and >2% of the viral population. Survival analysis was conducted to evaluate the association between the GSS and risk of TF (viral load >200 copies/mL plus treatment change).Results: Baseline NGS data were available for 1380 antiretroviral therapy (ART)‐naïve participants enrolled over 2009–2013. First‐line ART included a non‐nucleoside reverse transcriptase inhibitor (NNRTI) in 976 (71%), a boosted protease inhibitor in 297 (22%), or an integrase strand transfer inhibitor in 107 (8%). The proportions of participants with GSS 20%, 10% for >5%, and 17% for the >2% thresholds, respectively. The adjusted hazard ratio of TF associated with a GSS of 0–2.75 versus 3 in the subset of participants with mutations detected at the >2% threshold was 1.66 (95% confidence interval 1.01–2.74; p = 0.05) and 2.32 (95% confidence interval 1.32–4.09; p = 0.003) after restricting the analysis to participants who started an NNRTI‐based regimen.Conclusions: Up to 17% of participants initiated ART with a GSS <3 on the basis of NGS data. Minority variants were predictive of TF, especially for participants starting NNRTI‐based regimens.

27 May 2019 in Viruses
Verified
Journal Article
Open access
PDF file
FGFrancesca Di Giallonardo
Francesca Di Giallonardo
APAngie N. Pinto
Angie N. Pinto
PKPhillip Keen
Phillip Keen
ASAnsari Shaik
Ansari Shaik
ACAlex Carrera
Alex Carrera
AKAnthony D. Kelleher
Anthony D. Kelleher
Australia’s response to the human immunodeficiency virus type 1 (HIV-1) pandemic led to effective control of HIV transmission and one of the world’s lowest HIV incidence rates—0.14%. Although there has been a recent decline in new HIV diagnoses in New South Wales (NSW), the most populous state in Australia, there has been a concomitant increase with non-B subtype infections, particularly for the HIV-1 circulating recombinant form CRF01_AE. This aforementioned CRF01_AE sampled in NSW, were combined with those sampled globally to identify NSW-specific viral clades. The population growth of these clades was assessed in two-year period intervals from 2009 to 2017. Overall, 109 NSW-specific clades were identified, most comprising pairs of sequences; however, five large clades comprising ≥10 sequences were also found. Forty-four clades grew over time with one or two sequences added to each in different two-year periods. Importantly, while 10 of these clades have seemingly discontinued, the remaining 34 were still active in 2016/2017. Seven such clades each comprised ≥10 sequences, and are representative of individual sub-epidemics in NSW. Thus, although the majority of new CRF01_AE infections were associated with small clades that rarely establish ongoing chains of local transmission, individual sub-epidemics are present and should be closely monitored.

6 December 2020 in Viruses
Verified
Journal Article
Open access
PDF file
FGFrancesca Di Giallonardo
Francesca Di Giallonardo
APAngie N. Pinto
Angie N. Pinto
PKPhillip Keen
Phillip Keen
ASAnsari Shaik
Ansari Shaik
ACAlex Carrera
Alex Carrera
OPon behalf of the NSW HIV Prevention Partnership Project
on behalf of the NSW HIV Prevention Partnership Project
Changes over time in HIV-1 subtype diversity within a population reflect changes in factors influencing the development of local epidemics. Here we report on the genetic diversity of 2364 reverse transcriptase sequences from people living with HIV-1 in New South Wales (NSW) notified between 2004 and 2018. These data represent >70% of all new HIV-1 notifications in the state over this period. Phylogenetic analysis was performed to identify subtype-specific transmission clusters. Subtype B and non-B infections differed across all demographics analysed (p < 0.001). We found a strong positive association for infections among females, individuals not born in Australia or reporting heterosexual transmission being of non-B origin. Further, we found an overall increase in non-B infections among men who have sex with men from 50 to 79% in the last 10 years. However, we also found differences between non-B subtypes; heterosexual transmission was positively associated with subtype C only. In addition, the majority of subtype B infections were associated with clusters, while the majority of non-B infections were singletons. However, we found seven non-B clusters (≥5 sequences) indicative of local ongoing transmission. In conclusion, we present how the HIV-1 epidemic has changed over time in NSW, becoming more heterogeneous with distinct subtype-specific demographic associations.

14 May 2022 in Journal of Medical Virology
Verified
Journal Article
Open access
Ki Wook KimKi Wook Kim
Ki Wook Kim
WXWang Xinye
Wang Xinye
AAAnurag Adhikari
Anurag Adhikari
MYMalinna Yeang
Malinna Yeang
FJFrances Jenkins
Frances Jenkins
SHSebastiaan Van Hal
Sebastiaan Van Hal